1.
Clin. transl. oncol. (Print)
; 12(5): 384-386, mayo 2010. tab, ilus
Artigo
em Inglês
| IBECS (Espanha)
| ID: ibc-124086
RESUMO
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) accounts for approximately 5% of Hodgkin's lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy (AU)